TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 788-795

  Miyamoto, Mitsuko ^a   Ohno, Michihiro ^a   Yamada, Naohiro ^a   Ohtake, Atsushi ^a   Matsushita, Teruo ^b  

^a Pharmaceutical Research Laboratories   (Japan)

^b NATIONAL FISHERIES UNIVERSITY   (Japan)

Author keywords

Platelet leukocyte interaction; Prostacyclin receptor agonist; Thromboxane A2 receptor antagonist

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ADRENALIN; BERAPROST; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TRA 418; UNCLASSIFIED DRUG;

ARTICLE; CELL INTERACTION; CONCENTRATION RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IC 50; LEUKOCYTE; MALE; MONOCYTE; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; BLOOD PLATELETS; CELL COMMUNICATION; CELL SEPARATION; CELLS, CULTURED; EPINEPHRINE; EPOPROSTENOL; FLOW CYTOMETRY; HUMANS; HYDRAZINES; LEUKOCYTES; OXAZINES; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; RECEPTORS, EPOPROSTENOL; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOSIS;

EID: 77958117586     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-09-0622     Document Type: Article

References (43)

1. Li N, Hu H, Lindqvist M, et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-2708.
2. Barnard MR, Linden MD, Frelinger AL 3rd, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005; 3: 2563-2570.
3. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
4. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil- interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99-111.
5. McEver RP. Regulation of function and expression of P-selectin. Agents Actions Suppl 1995; 47: 117-119.
6. Brambilla M, Camera M, Colnago D, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 2008; 28: 947-953. (Pubitemid 351544112)
7. Botto N, Sbrana S, Trianni G, et al. An increased platelet-leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: a pathogenic role for "no-reflow" phenomenon? Int J Cardiol 2007; 117: 123-130.
8. Shoji T, Koyama H, Fukumoto S, et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006; 188: 190-195. (Pubitemid 44142541)
9. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130-2132. (Pubitemid 34517152)
10. Ogura H, Kawasaki T, Tanaka H, et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-809. (Pubitemid 32499602)
11. 2 receptor antagonists and prostacyclin receptor agonists. Bioorg Med Chem 2006; 14: 2005-2021.
12. 2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991; 84: 1568-1580.
13. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166-181.
14. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188-1192.
15. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182. (Pubitemid 30061277)
16. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804. (Pubitemid 34229650)
17. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002; 62: 107-133.
18. Mohler ER 3rd, Klugherz B, Goldman R, et al. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med 2000; 5: 231-237. (Pubitemid 32117856)
19. Ylitalo P, Kaukinen S, Reinikainen P, et al. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. Int J Clin Pharmacol Ther Toxicol 1990; 28: 197-204. (Pubitemid 20207626)
20. Sakai A, Yajima M, Nishio S. Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci 1990; 47: 711-719. (Pubitemid 20262153)
21. Mazzone A, Cusa C, Bucci L, et al. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 1999; 29: 1-5. (Pubitemid 29084241)
22. Ishikawa S, Kawasaki A, Neya K, et al. Beraprost sodium-induced hypotension in two patients after cardiac surgery. Int Heart J 2006; 47: 319-323.
23. 2 receptor antagonistic and prostaglandin I2 receptor agonistic activities: its antiplatelet effects in human and animal platelets. J Thromb Haemost 2003; 1: 1813-1819.
24. Miyamoto M, Yamada N, Ikezawa S, et al. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol 2003; 140: 889-894. (Pubitemid 37464071)
25. Izzi B, Pampuch A, Costanzo S, et al. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thromb Haemost 2007; 98: 1276-1284. (Pubitemid 350239099)
26. Hagberg IA, Lyberg T. Evaluation of circulating platelet-leukocyte conjugates: a sensitive flow cytometric assay well suited for clinical studies. Platelets 2000; 11: 151-160. (Pubitemid 30345422)
27. Tsai NW, Chang WN, Shaw CF, et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 2009; 124: 213-218.
28. Hjemdahl P, Chronos NA, Wilson DJ, et al. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb 1994; 14: 77-84.
29. Wang JS, Cheng LJ. Effect of strenuous, acute exercise on alpha2-adrenergic agonist- potentiated platelet activation. Arterioscler Thromb Vasc Biol 1999; 19: 1559-1565.
30. Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists. Blood 1989; 73: 150-158. (Pubitemid 19040969)
31. Horn NA, Anastase DM, Hecker KE, et al. Epinephrine enhances platelet-neutrophil adhesion in whole blood in vitro. Anesth Analg 2005; 100: 520-526.
32. Tarnow I, Kristensen AT, Krogh AK, et al. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol 2008; 123: 345-352.
33. Konstantopoulos K, Neelamegham S, Burns AR, et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998; 98: 873-882. (Pubitemid 28397437)
34. Nishio S, Matsuura H, Kanai N, et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988; 47: 1-10.
35. Macfarlane DE, Stump DC. Parallel observation of the occupancy of the alpha 2-adrenergic receptor in intact platelets and its ability to inhibit the adenylate cyclase. Mol Pharmacol 1982; 22: 574-579.
36. Tárnok A, Mahnke A, Müller M, et al. Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leukocyte aggregation. Cytometry 1999; 38: 30-39. (Pubitemid 29114258)
37. Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte- platelet adhesion. Blood 1992; 79: 1201-1205.
38. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204. (Pubitemid 30470302)
39. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-2093. (Pubitemid 27459364)
40. Nicolini FA, Mehta P, Lawson D, et al. Reduction in human neutrophil chemotaxis by the prostacyclin analogue iloprost. Thromb Res 1990; 59: 669-674. (Pubitemid 20330346)
41. Kainoh M, Imai R, Umetsu T, et al. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 477-484. (Pubitemid 20041915)
42. Czeslick EG, Simm A, Grond S, et al. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 2003; 33: 1013-1017. (Pubitemid 37421601)
43. Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor( s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997; 122: 149-157.